Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets

Biochemical and Biophysical Research Communications

Volumn 385, Issue 1, 2009, Pages 100-105

  Yu, Liang ^a,b   Mohanram, Venkatramanan ^a   Simonson, Oscar E ^a   Smith, C I Edvard ^a   Spetz, Anna Lena ^a   Mohamed, Abdalla J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; HIV 1; Itk; LTR; NF B; Proteasome inhibitor; Transcription

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; INDINAVIR; INTERLEUKIN 2; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSCRIPTION TERMINATION; VIRUS GENE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; BORONIC ACIDS; CYSTEINE PROTEINASE INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MICE; MICE, INBRED STRAINS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67349234137     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.156     Document Type: Article

References (28)

1. Calmy A., Hirschel B., Cooper D.A., and Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 370 (2007) 12-14
2. Adamson C.S., and Freed E.O. Recent progress in antiretrovirals - lessons from resistance. Drug Discov. Today 13 (2008) 424-432
3. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6 (2007) 959-966
4. Nabel G., and Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326 (1987) 711-713
5. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006) 431-436
6. Hoeller D., Hecker C.M., and Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 6 (2006) 776-788
7. Nakayama K.I., and Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6 (2006) 369-381
8. Manochakian R., Miller K.C., and Chanan-Khan A.A. Clinical impact of Bortezomib in frontline regimens for patients with multiple myeloma. Oncologist 12 (2007) 978-990
9. Yu L., Mohamed A.J., Simonson O.E., Vargas L., Blomberg K.E., Bjorkstrand B., Arteaga H.J., Nore B.F., and Smith C.I. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 111 (2008) 4617-4626
10. Berg L.J., Finkelstein L.D., Lucas J.A., and Schwartzberg P.L. Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol. 23 (2005) 549-600
11. Readinger J.A., Schiralli G.M., Jiang J.K., Thomas C.J., August A., Henderson A.J., and Schwartzberg P.L. Selective targeting of ITK blocks multiple steps of HIV replication. Proc. Natl. Acad. Sci. USA 105 (2008) 6684-6689
12. Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P., and Smith C.I. Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1. J. Biol. Chem. 281 (2006) 18201-18207
13. Coiras M., Lopez-Huertas M.R., Rullas J., Mittelbrunn M., and Alcami J. Basal shuttle of NF-kappaB/I kappaB alpha in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology 4 (2007) 56
14. Yun Z., Fredriksson E., and Sonnerborg A. Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay. J. Clin. Microbiol. 40 (2002) 3883-3884
15. Lee C., Kim J., Shin S.G., and Hwang S. Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. J. Biotechnol. 123 (2006) 273-280
16. Wu Y., and Marsh J.W. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293 (2001) 1503-1506
17. Pawinski T., Pulik P., Gralak B., and Horban A. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. Acta Pol. Pharm. 65 (2008) 93-100
18. Schwartz O., Marechal V., Friguet B., Arenzana-Seisdedos F., and Heard J.M. Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J. Virol. 72 (1998) 3845-3850
19. Arteaga H.J., Hinkula J., van Dijk-Hard I., Dilber M.S., Wahren B., Christensson B., Mohamed A.J., and Smith C.I. Choosing CCR5 or Rev siRNA in HIV-1. Nat. Biotechnol. 21 (2003) 230-231
20. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., and Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 (2008) 921-926
21. + T cells is markedly enhanced in the setting of antigen-specific immune activation. J. Exp. Med. 183 (1996) 687-692
22. Annibaldi A., Sajeva A., Muscolini M., Ciccosanti F., Corazzari M., Piacentini M., and Tuosto L. CD28 ligation in the absence of TCR promotes RelA/NF-kappaB recruitment and trans-activation of the HIV-1 LTR. Eur. J. Immunol. 38 (2008) 1446-1451
23. Bishop K.N., Holmes R.K., Sheehy A.M., and Malim M.H. APOBEC-mediated editing of viral RNA. Science 305 (2004) 645
24. Sheehy A.M., Gaddis N.C., and Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
25. Schubert U., Ott D.E., Chertova E.N., Welker R., Tessmer U., Princiotta M.F., Bennink J.R., Krausslich H.G., and Yewdell J.W. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 97 (2000) 13057-13062
26. Wei B.L., Denton P.W., O'Neill E., Luo T., Foster J.L., and Garcia J.V. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection. J. Virol. 79 (2005) 5705-5712
27. Silvestri G., Paiardini M., Pandrea I., Lederman M.M., and Sodora D.L. Understanding the benign nature of SIV infection in natural hosts. J. Clin. Invest. 117 (2007) 3148-3154
28. + T cells. Immunology 124 (2008) 234-246